DOES REVISED INTERNATIONAL PROGNOSITIC SCORING SYSTEM (IPSS-R) HAVE ANY IMPACT ON CLINICAL OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS?

被引：0
|
作者：
Teo, Z. [1 ]
Yiu, R. [1 ]
Yueh, L. Ling [1 ]
Ho, A. [1 ]
机构：
[1] Singapore Gen Hosp, Singhlth, Haematol, Singapore, Singapore
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P747
引用
收藏
页码：312 / 313
页数：2
相关论文
共 50 条
  • [41] Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes
    Yoo Jin Lee
    Sung Woo Park
    In Hee Lee
    Jae Sook Ahn
    Hyeoung Joon Kim
    Joo Seop Chung
    Ho Jin Shin
    Won Sik Lee
    Sang Min Lee
    Young Don Joo
    Hawk Kim
    Ho Sup Lee
    Yang Soo Kim
    Yoon Young Cho
    Joon Ho Moon
    Sang Kyun Sohn
    Annals of Hematology, 2016, 95 : 1795 - 1804
  • [42] Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
    M G Della Porta
    H Tuechler
    L Malcovati
    J Schanz
    G Sanz
    G Garcia-Manero
    F Solé
    J M Bennett
    D Bowen
    P Fenaux
    F Dreyfus
    H Kantarjian
    A Kuendgen
    A Levis
    J Cermak
    C Fonatsch
    M M Le Beau
    M L Slovak
    O Krieger
    M Luebbert
    J Maciejewski
    S M M Magalhaes
    Y Miyazaki
    M Pfeilstöcker
    M A Sekeres
    W R Sperr
    R Stauder
    S Tauro
    P Valent
    T Vallespi
    A A van de Loosdrecht
    U Germing
    D Haase
    P L Greenberg
    M Cazzola
    Leukemia, 2015, 29 : 1502 - 1513
  • [43] Impact Of Revised-International Prognostic Scoring System (R-IPSS) Cytogenetic-Risk Stratification In Myelodysplastic Syndrome
    Otazo, Maria
    Yellapragada, Sarvari Venkata
    Zheng, Matthew
    Li, Ang
    Perez, Ruben Hernandez
    Rivero, Gustavo A.
    BLOOD, 2013, 122 (21)
  • [44] Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes
    Montoro, Julia
    Pomares, Helena
    Villacampa, Guillermo
    Merchan, Brayan
    Molero, Antonieta
    Alonso, Esther
    Gallur, Laura
    Grau, Javier
    Salamero, Olga
    Roldan, Elisa
    Saumell, Silvia
    Ortega, Margarita
    Sureda, Anna
    Bosch, Francesc
    Arnan, Montserrat
    Valcarcel, David
    LEUKEMIA & LYMPHOMA, 2019, 60 (06) : 1522 - 1527
  • [45] Treatment Sequence of Lenalidomide (LEN) and Hypomethylating Agents (HMAs) and the Impact on Clinical Outcomes for Patients with Myelodysplastic Syndromes (MDS)
    Zeidan, Amer M.
    Klink, Andrew J.
    Feinberg, Bruce
    McGuire, Michael
    BLOOD, 2017, 130
  • [46] Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)
    Calvo, Xavier
    Arenillas, Leonor
    Luno, Elisa
    Senent, Leonor
    Arnan, Montserrat
    Ramos, Fernando
    Pedro, Carme
    Tormo, Mar
    Montoro, Julia
    Diez-Campelo, Maria
    Blanco, Maria Laura
    Arrizabalaga, Beatriz
    Xicoy, Blanca
    Bonanad, Santiago
    Jerez, Andres
    Nomdedeu, Meritxell
    Ferrer, Ana
    Sanz, Guillermo F.
    Florensa, Lourdes
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (07) : 614 - 621
  • [47] Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes
    Zeidan, Amer M.
    Lee, Ju-Whei
    Prebet, Thomas
    Greenberg, Peter
    Sun, Zhuoxin
    Juckett, Mark
    Smith, Mitchell R.
    Paietta, Elisabeth
    Gabrilove, Janice
    Erba, Harry P.
    Tallman, Martin S.
    Gore, Steven D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (03) : 352 - 359
  • [48] High Predictive Value of the Revised International Prognostic Scoring System (IPSS-R): An External Analysis of 646 Patients From a Multiregional Italian MDS Registry
    Messa, Emanuela
    Gioia, Daniela
    Evangelista, Andrea
    Allione, Bernardino
    Angelucci, Emanuele
    Balleari, Enrico
    Calabrese, Marco
    Catarini, Massimo
    Centurioni, Riccardo
    Danise, Paolo
    Del Corso, Liset
    Masiera, Elisa
    Musto, Pellegrino
    Pane, Fabrizio
    Poloni, Antonella
    Sanna, Alessandro
    Tassara, Rodolfo
    Ciccone, Gianni
    Levis, Alessandro
    Saglio, Giuseppe
    Santini, Valeria
    BLOOD, 2012, 120 (21)
  • [49] IMPACT OF THE MUTATIONAL PROFILE AT THE TIME OF DIAGNOSIS IN RESPONSE OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA TREATED WITH HYPOMETHYLATING AGENTS
    Montalban-Bravo, G.
    Alfonso, A.
    Patel, K.
    Jabbour, E.
    Benton, C.
    Kadia, T.
    Ravandi, F.
    Cortes, J.
    DiNardo, C.
    Daver, N.
    Borthakur, G.
    Pemmaraju, N.
    Konopleva, M.
    Ganan-Gomez, I.
    Nogueras-Gonzalez, G.
    Huang, X.
    Wang, F.
    Xingzhi, S.
    Bueso-Ramos, C.
    Futreal, A.
    Kantarjian, H.
    Takahashi, K.
    Garcia-Manero, G.
    HAEMATOLOGICA, 2017, 102 : 184 - 184
  • [50] Utility Of Revised International Prognostic Scoring System (R-IPSS) To Predict Outcome Of Myelodysplastic Syndromes (MDS) Patients After Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
    Corrales-Yepez, Maria Gabriela
    Field, Teresa
    List, Alan
    Anasetti, Claudio
    Perkins, Janelle
    Al Ali, Najla H.
    Mishra, Asmita
    Padron, Eric
    Lancet, Jeffrey E.
    Kharfan-Dabaja, Mohamed A.
    Komrokji, Rami S.
    BLOOD, 2013, 122 (21)
12345